Study Summary: Alzheimer's Disease
Gooey Rabinski
Founder at Higher Learning LV and technical writer and instructional developer
"I love your articles. Informative, rich, clean. Amazing work." — Miriam Sanger, cannabis journalist, Ra'ananna, Central, Israel, August 2020
"A growth mindset requires us to seek new information to survive. Curt is the fountain of youth when it comes to cannabis knowledge!" — Flow Scientific, British Columbia, Canada, August 2020
"If you aren’t following Curt Robbins, you are missing out on one of the smartest people in cannabis." — Cannabis & Tech Today Magazine, 2020
"Great content! So informative, especially on the historical details!" — Andreas Mueller, Baden-Wurttemberg, Germany, 2018
"Curt Robbins from California is an encyclopedia of cannabis knowledge." — Ian Jessop, Cannabis Health Radio, 2017
Don't forget to follow my social media hashtags #LearnAndTeachOthers?and #TeachYourselfTerpenes?to learn something new every day!
Copyright ? 2020 by Curt Robbins. All Rights Reserved.
Alzheimer's disease (also known as Alzheimer disease or simply Alzheimers) was discovered in 1906 by Dr. Alois Alzheimer, who diagnosed it following an autopsy on the brain of a woman who died of an unknown mental illness.
Alzheimer's disease actually begins damaging the brain up to a decade prior to the onset of any form of short-term memory loss. It is this memory loss that is the infamous first symptom of the disease.
Copyright ? 2018-2020 by Curt Robbins. All Rights Reserved.
Alzheimer's disease is the sixth leading cause of death in the United States and plagues about five million Americans. It is a progressive neurodegenerative brain disorder and the most common form of dementia. In fact, it is estimated that Alzheimer disease causes 60 to 70 percent of all cases of dementia. One in three senior citizens will eventually die from this disease or another form of dementia.
2016 Israeli Study
While previous research has already revealed the benefits of cannabis in the treatment of neurological disorders, including Alzheimers and Parkinson’s, a new study confirms previous findings.
A 2016 research study entitled "Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia" that was published in the Journal of Alzheimer's Disease involved a team from Israel comprised of medical researchers from Tel-Aviv University and Bar-Ilan University.
The researchers added medical cannabis oil to the treatment regimens of a small group of patients suffering from Alzheimer’s. Researches administered the medical cannabis oil to deliver THC to study participants. The objective of the study was to measure the efficacy and safety of cannabis oil as a supplement to traditional pharmacotherapy for the relief of “behavioral and psychological symptoms of dementia.”
Concluded the study:
“Adding medical cannabis oil to Alzheimer’s disease patients’ pharmacotherapy is safe and a promising treatment option.”
This study was conducted to further explore the previously proven background that “Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD).”
Cannabis has also been proven to provide relief from several other symptoms of aging experienced by seniors, including arthritis, chronic pain and loss of appetite. While initial studies are promising, the neuroprotective qualities of the plant should be explored further.
Copyright ? 2006-2020 by Curt Robbins. All Rights Reserved.
Don't forget to follow my social media hashtags #LearnAndTeachOthers?and #TeachYourselfTerpenes?to learn something new every day!
Copyright ? 2020 by Curt Robbins. All Rights Reserved.
About The Author
Curt Robbins is a technical writer, instructional designer, and lecturer who has been developing science-based educational and training content for Fortune 200 enterprises for more than 30 years. His clients have included Federal Express, Microsoft, Sun Microsystems, Northrop Grumman, National City Bank, Strainprint Technologies Ltd., the J.M. Smucker Company, and USAA.
Robbins has developed more than 600 educational articles regarding hemp and its various health components, including terpenes, cannabinoids, and the human endocannabinoid system for clients in the U.S., Canada, and Israel. His latest white paper, CBG: The Mother of Cannabinoids, is an evidence-based 50-page deep dive into the biochemistry of the hemp-derived phytocannabinoid cannabigerol that features 60 peer-reviewed research study citations.
Robbins currently serves as Director of Curriculum Development for Higher Learning LV? based in Las Vegas, Nevada. Robbins can be found on Twitter at @RobbinsGroupLLC and via email at [email protected]. To learn more, search for his social media hashtag campaigns on your favorite social media network:
- #LearnAndTeachOthers?
- #TeachYourselfTerpenes?
- #ChasingAnandamide?
